A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
Coppo et al.
Blood
2021; 137(6): 733–742.
This article was published on February 11, 2021, at ashpublications.org.
DOI: 10.1182/blood.2020008021
Select your desired language:
English
German | Deutsch
Spanish | Español
French | Français
Italian | Italiano
Japanese | 日本語
English
Access ePrint
German | Deutsch
Access ePrint
English version without login
Spanish | Español
Access ePrint
French | Français
Access ePrint
Italian | Italiano
Access ePrint
Japanese | 日本語
Access ePrint
Extra: Additional Content
TTP: the evolution of clinical practice
Access ePrint
Blood Podcast: Season 2, Episode 6
Featuring a discussion of the Coppo trial
To access all episodes of the Blood Podcast, on a range of hematology topics, please click here
Content © 2021 by The American Society of Hematology
Site provided by
Springer Healthcare
. Part of the
Springer Nature Group
.
Privacy Policy